Medication-info.com Search Menu

Voranigo (Vorasidenib): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
10 mg, 40 mg
Active ingredient:
Similar drugs:

Patient information: uses, side effects, how to take - Voranigo

What is VORANIGO?

VORANIGO is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery.

Your healthcare provider will perform a test to make sure that VORANIGO is right for you.

It is not known if VORANIGO is safe and effective in children under 12 years of age.

Before taking VORANIGO, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems
  • have kidney problems or are on dialysis
  • smoke tobacco
  • are pregnant or plan to become pregnant. VORANIGO can harm your unborn baby.

    Females who are able to become pregnant:

    • Your healthcare provider will do a pregnancy test before you start treatment with VORANIGO.
    • You should use effective nonhormonal birth control during treatment with VORANIGO and for 3 months after the last dose. VORANIGO may affect how hormonal contraceptives (birth control) work and cause them to not work well. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VORANIGO.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VORANIGO.

    Males with female partners who are able to become pregnant:

    • You should use effective birth control during treatment with VORANIGO and for 3 months after the last dose.
    • Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant during your treatment with VORANIGO.
  • are breastfeeding or plan to breastfeed. It is not known if VORANIGO passes into breast milk. Do not breastfeed during treatment with VORANIGO and for 2 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. VORANIGO may affect the way other medicines work and other medicines may affect how VORANIGO works.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take VORANIGO?

  • Take VORANIGO exactly as your healthcare provider tells you.
  • Do not change your dose or stop taking VORANIGO without talking to your healthcare provider.
  • Take VORANIGO 1 time a day about the same time each day.
  • Swallow VORANIGO tablets whole with water. Do not split, crush or chew the tablets.
  • VORANIGO can be taken with or without food.

  • If you miss a dose of VORANIGO by less than 6 hours, take the missed dose right away. If you miss a dose by more than 6 hours, skip the dose for that day. Take your next dose at your usual time.
  • If you vomit after taking VORANIGO, do not take an extra dose. Take your next dose at your usual time.

What are the possible side effects of VORANIGO?

VORANIGO may cause serious side effects, including:

  • Liver problems. Changes in liver function blood tests may happen during treatment with VORANIGO and can be serious. Your healthcare provider will do blood tests to check your liver function before and during treatment with VORANIGO. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems:

    • yellowing of your skin or the white part of your eyes (jaundice)
    • dark tea-colored urine
    • loss of appetite
    • pain on the upper right side of your stomach area
    • feeling very tired or weak

The most common side effects of VORANIGO include:

  • increased liver enzyme levels in the blood
  • lack of energy, tiredness
  • headache
  • COVID-19
  • muscle aches or stiffness
  • diarrhea
  • nausea
  • seizure

Your healthcare provider may change your dose, temporarily stop or permanently stop treatment with VORANIGO if you have certain side effects.

VORANIGO may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of VORANIGO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store VORANIGO?

  • Store VORANIGO at room temperature between 68°F to 77°F (20°C to 25°C).
  • VORANIGO comes with desiccant canisters (drying agent) in the bottle to help keep the medicine dry (protect from moisture). Do not remove the desiccant canisters from the bottle. Do not swallow the desiccant canisters.
  • The VORANIGO bottle has a child resistant cap.

Keep VORANIGO and all medicines out of reach of children.

General information about the safe and effective use of VORANIGO.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VORANIGO for a condition for which it was not prescribed. Do not give VORANIGO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VORANIGO that is written for health professionals.

What are the ingredients in VORANIGO?

Active ingredient: vorasidenib

Inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicified microcrystalline cellulose and sodium lauryl sulfate

Tablet coating: hypromellose, lactose monohydrate, macrogol and titanium dioxide

Black printing ink: black iron oxide, hypromellose and propylene glycol

Manufactured for Servier Pharmaceuticals LLC, Boston, MA 02210

Servier and the Servier logo are trademarks of Les Laboratoires Servier.

VORANIGO® is a registered trademark of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier.

© 2024 Servier Pharmaceuticals LLC

For more information, go to www.VORANIGO.com or call 1-800-807-6124.

This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 08/2024

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 218784 · View the label on DailyMed

Revision date stated in the text: August 2024

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Voranigo

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Isocitrate Dehydrogenase 1 Inhibitor, Isocitrate Dehydrogenase 2 Inhibitor
Active ingredient Vorasidenib
Dosage form Tablet, film coated
Route Oral
Marketing status listed in the FDA NDC Directory
Company (applicant) SERVIER
FDA approval NDA 218784New Drug Application (NDA) Approved August 6, 2024
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
10 mg – 30 in 1 bottle / 1 in 1 carton NDC 72694-879-10
40 mg – 30 in 1 bottle / 1 in 1 carton NDC 72694-728-40

Source: FDA drug labeling via NLM DailyMed, data as of November 11, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.